65,437 trials
HIV/AIDS
Primary: Percent of Participants That Scheduled an Appointment for PrEP Consultation. — 10; 11 Participants — p=.88
Atopic Dermatitis
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 — 48.2…
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants
Heart Failure, Systolic · Heart Failure
Primary: Knowledge About Defibrillation at Baseline — 53.4; 55.4 score on a scale
Rosacea
Primary: Efficacy Absolute Change in Inflammatory Lesion Count — -19.8; -20.9 Lesions — p=0.799
Lung Preservation
Primary: A Composite of Patient Survival at Day 30 Post Transplantation, and Absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction…
Locally Advanced Rectal Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC) — 0; 1; 1; 3 Participants
Lung Transplant
Primary: Number of Participants With Composite Endpoint of Patient Survival at Day-30 Post Transplant and Absence of Primary Graft Dysfunction (PGD) Grade 3 During the First 72…
Lupus Arthritis
Primary: Number of Participants With Adverse Events (AEs) — 21; 29; 25 Participants
Arthroplasty Complications
Primary: Number of Patients With Early Complication — 9; 16; 4 Participants
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Healthy
Primary: Area Under the Concentration-time Curve of BI 1265162 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Dose-normalized, (AUC0-∞, Norm) — 44.63; 0.22…
Skin Infection
Primary: Status of Subject's Clinical Responses — 10; 1 participants
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Rosacea
Primary: Number of Subjects With 1 or More Treatment-related Treatment-Emergent Adverse Events — 48 participants